Resmetirom would be the first approved treatment in an area that’s seen failure after failure, including Intercept’s closely watched FXR agonistFXR agonist obeticholic acid, which was rejected for a second time in June following safety concerns. Madrigal completed its submission shortly after Intercept’s CRL, though its candidate relies on a different mechanism of action known as thyroid hormone beta-receptor agonism.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.